# KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

> **NCT06400303** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Kyverna Therapeutics** · enrollment: 3 (actual)

## Conditions studied

- Systemic Sclerosis
- Systemic Sclerosis - Diffuse Cutaneous
- Systemic Sclerosis - 2013 ACR/EULAR Classification Criteria

## Interventions

- **BIOLOGICAL:** KYV-101
- **DRUG:** Standard lymphodepletion regimen

## Key facts

- **NCT ID:** NCT06400303
- **Lead sponsor:** Kyverna Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-08-06
- **Primary completion:** 2026-03
- **Final completion:** 2027-03
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2025-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06400303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06400303, "KYSA-5: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06400303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*